Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Halozyme Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 637
- +29 vs. Q4 2025
- Shares held
- 120.5M
- +11.0M (+10.0%) vs. Q4 2025
- Total value
- $7.79B
- +$419.9M (+5.7%) vs. Q4 2025
- New holders
- 98
- 236 more added
- Sold out
- 69
- 214 more reduced
11 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HALO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 674 | $9.62B |
| Q1 2026 | 637 | $7.79B |
| Q4 2025 | 619 | $8.29B |
| Q3 2025 | 604 | $8.75B |
| Q2 2025 | 552 | $6.05B |
| Q1 2025 | 550 | $7.72B |
| Q4 2024 | 509 | $5.86B |
| Q3 2024 | 510 | $7.17B |
| Q2 2024 | 460 | $6.40B |
| Q1 2024 | 413 | $5.03B |
| Q4 2023 | 411 | $4.62B |
| Q3 2023 | 390 | $4.71B |
| Q2 2023 | 370 | $4.45B |
| Q1 2023 | 387 | $4.77B |
| Q4 2022 | 423 | $7.35B |
| Q3 2022 | 357 | $5.21B |
| Q2 2022 | 368 | $5.65B |
| Q1 2022 | 316 | $5.12B |
| Q4 2021 | 326 | $5.21B |
| Q3 2021 | 326 | $5.29B |
| Q2 2021 | 315 | $5.89B |
| Q1 2021 | 337 | $5.53B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Halozyme Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Investors Portfolio Services LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Annis Gardner Whiting Capital Advisors, LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| DV Trading LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| ROSS\JOHNSON & Associates LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Nemes Rush Group LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Avion Wealth | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Norges Bank | – | – | – | – | Not filed |
| Meritage Portfolio Management | – | – | – | – | Not filed |
| Brandywine Global Investment Management, LLC | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |
| NDVR, Inc. | – | – | – | – | Not filed |
| EMC Capital Management | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |
| Trust Co of Vermont | – | – | – | – | Not filed |
| ORG Partners LLC | – | – | – | – | Not filed |